Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Licensing Agreement with Cannabis Edibles Infusion Manufacturer
Lexaria enters agreement with Biolog for Lexaria’s DehydraTECH™ technology in return for royalties on sales revenue and licensing fees Biolog has exclusive rights to use the Lexaria technology for its particular applications for five years Lexaria is the only company worldwide with patent issued for oral delivery CBD and all other non-psychoactive cannabinoids Based in Kelowna, British Columbia, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced on February 27, 2018, its entry into a technology licensing agreement with Biolog, Inc. for the provision of Lexaria’s patented DehydraTECH™ technology (http://cnw.fm/pY0oG). Lexaria’s proprietary technology will be used in the formulation of a…